Table I.
Group | ROS, fluorescence intensity | MDA, nmol/ml | 8-OHdG, ng/ml | TNF-α, pg/ml | IL-6, pg/ml | IL-1β, pg/ml |
---|---|---|---|---|---|---|
NG | 214.03±24.91 | 2.42±0.51 | 2.99±0.62 | 8.51±1.84 | 10.56±2.13 | 15.25±3.48 |
NG + Hemin | 135.73±12.42a | 1.59±0.23a | 1.41±0.20a | 3.48±0.82a | 4.71±0.82a | 6.59±1.97a |
NG + CrMP | 238.46±27.31 | 2.68±0.65 | 3.55±0.71 | 10.72±1.98 | 12.92±2.99 | 18.65±4.09 |
NG + Hemin + CrMP | 227.52±23.74 | 2.51±0.42 | 3.02±0.63 | 9.13±1.79 | 11.37±2.11 | 16.99±4.31 |
AGEs + NG | 892.48±50.27a | 6.27±0.78a | 8.39±0.85a | 30.81±4.63a | 39.88±5.97a | 48.85±6.27a |
AGEs + NG + Hemin | 485.32±38.64b | 3.98±0.71b | 3.22±0.72b | 11.56±2.01b | 21.96±3.63b | 23.26±5.24b |
AGEs + NG + CrMP | 917.60±62.84 | 6.94±0.81 | 9.78±0.96 | 38.55±5.09 | 42.42±6.56 | 55.43±7.38 |
AGEs + NG + Hemin + CrMP | 901.25±60.35 | 6.68±0.79 | 8.52±0.84 | 32.79±5.11 | 40.71±6.71 | 52.83±7.50 |
AGEs + HG | 1,183.73+79.37a,b | 8.83±0.86a,b | 10.97±1.23a,b | 39.63±5.94a,b | 48.68±7.02a,b | 60.13±7.62a,b |
AGEs + HG + Hemin | 582.16±41.38c | 4.62±0.76c | 5.63±0.88c | 15.38±2.32c | 22.53±4.39c | 32.86±5.89c |
AGEs + HG + CrMP | 1,294.31±83.65 | 9.41±0.92 | 12.85±1.40 | 45.83±6.84 | 52.50±7.58 | 65.73±7.97 |
AGEs + HG + Hemin + CrMP | 1,206.39±80.15 | 8.96±0.83 | 11.09±1.14 | 42.09±6.58 | 50.15±6.91 | 62.92±7.25 |
Data are presented as the mean ± SD (n=3).
aP<0.05 vs. NG group;
bP<0.05 vs. AGEs + NG group;
cP<0.05 vs. AGEs + HG group. NG, normal glucose; HG, high glucose; AGEs, advanced glycation end products; CrMP, chromium mesoporphyrin; ROS, reactive oxygen species; MDA, malondialdehyde; 8-OHdG, 8-hydroxydeoxyguanosine.